1
Laboratori de Fisiologia Molecular, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, 08003 Barcelona, Spain
2
Genetic Medicine and Rare Diseases Pediatric Institute, Hospital Sant Joan de Déu, 08002 Barcelona, Spain
3
Unit of Child Neurology, Department of Pediatrics, Hospital Infantil Universitario Niño Jesús de Madrid, 28009 Madrid, Spain
4
Neuropediatric, Radiology and Clinical Biochemistry Departments, Hospital Sant Joan de Déu, 08002 Barcelona, Spain
5
U-703 Centre for Biomedical Research on Rare Diseases (CIBER-ER), Instituto de Salud Carlos III, 08002 Barcelona, Spain
6
Pediatric Department, Hospital Virgen de la Salud, 45004 Toledo, Spain
7
Pediatric Neurology Unit, Pediatrics Department, Hospital Universitario Rio Hortega, 47012 Valladolid, Spain
8
Neuropediatric Department, Pediatric Service, Hospital Universitario Severo Ochoa, Leganés, 28009 Madrid, Spain
9
Statistics Department, Fundació Sant Joan de Déu, 08002 Barcelona, Spain
10
Centro de Diagnóstico de Enfermedades Moleculares (CEDEM), Universidad Autónoma de Madrid (UAM), U-746 Centre for Biomedical Research on Rare Diseases (CIBER-ER) Madrid, Instituto de Salud Carlos III, IdiPAZ, 28009 Madrid, Spain
11
Grup de Recerca en Neurologia Pediàtrica, Institut de Recerca Vall d’Hebron, Universitat Autònoma de Barcelona, Secció de Neurologia Pediàtrica, Hospital Universitari Vall d’Hebron, 08002 Barcelona, Spain
†
Both authors contributed equally to this work.
add
Show full affiliation list
remove
Hide full affiliation list
Abstract
Stroke-like episodes (SLE) occur in phosphomannomutase deficiency (PMM2-CDG), and may complicate the course of channelopathies related to Familial Hemiplegic Migraine (FHM) caused by mutations in
CACNA1A (encoding Ca
V2.1 channel). The underlying pathomechanisms are unknown. We analyze clinical variables to detect risk
[...] Read more.
Stroke-like episodes (SLE) occur in phosphomannomutase deficiency (PMM2-CDG), and may complicate the course of channelopathies related to Familial Hemiplegic Migraine (FHM) caused by mutations in
CACNA1A (encoding Ca
V2.1 channel). The underlying pathomechanisms are unknown. We analyze clinical variables to detect risk factors for SLE in a series of 43 PMM2-CDG patients. We explore the hypothesis of abnormal Ca
V2.1 function due to aberrant
N-glycosylation as a potential novel pathomechanism of SLE and ataxia in PMM2-CDG by using whole-cell patch-clamp,
N-glycosylation blockade and mutagenesis. Nine SLE were identified. Neuroimages showed no signs of stroke. Comparison of characteristics between SLE positive versus negative patients’ group showed no differences. Acute and chronic phenotypes of patients with PMM2-CDG or
CACNA1A channelopathies show similarities. Hypoglycosylation of both Ca
V2.1 subunits (?
1A and ?
2?) induced gain-of-function effects on channel gating that mirrored those reported for pathogenic
CACNA1A mutations linked to FHM and ataxia. Unoccupied
N-glycosylation site N283 at ?
1A contributes to a gain-of-function by lessening Ca
V2.1 inactivation. Hypoglycosylation of the ?
2? subunit also participates in the gain-of-function effect by promoting voltage-dependent opening of the Ca
V2.1 channel. Ca
V2.1 hypoglycosylation may cause ataxia and SLEs in PMM2-CDG patients. Aberrant Ca
V2.1
N-glycosylation as a novel pathomechanism in PMM2-CDG opens new therapeutic possibilities.
Full article